Nitric oxide donor and non steroidal anti inflammatory drugs as a therapy for muscular dystrophies: Evidence from a safety study with pilot efficacy measures in adult dystrophic patients

Pharmacological Research

Volumn 65, Issue 4, 2012, Pages 472-479

  D'Angelo, Maria Grazia ^a   Gandossini, Sandra ^a   Boneschi, Filippo Martinelli ^b   Sciorati, Clara ^b   Bonato, Sara ^a   Brighina, Erika ^a   Comi, Giacomo Pietro ^c   Turconi, Anna Carla ^a   Magri, Francesca ^c   Stefanoni, Giuseppe ^a   Brunelli, Silvia ^d   Bresolin, Nereo ^a,c   Cattaneo, Dario ^c   Clementi, Emilio ^a,c  

^a SCIENTIFIC INSTITUTE   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Anti inflammatory drug; Muscular dystrophies; Nitric oxide donor; Pharmacological treatment; Safety

Indexed keywords

IBUPROFEN; ISOSORBIDE DINITRATE;

ADULT; BECKER MUSCULAR DYSTROPHY; BLOOD EXAMINATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUCHENNE MUSCULAR DYSTROPHY; EPIGASTRIC PAIN; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART FUNCTION TEST; HUMAN; LEG EDEMA; LEUKOCYTE COUNT; LIMB GIRDLE MUSCULAR DYSTROPHY; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; METEORISM; MUSCULAR DYSTROPHY; OPEN STUDY; ORTHOSTATIC HYPOTENSION; PHYSICAL EXAMINATION; PILOT STUDY; PRECORDIAL PAIN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TACHYCARDIA; TREATMENT OUTCOME;

EID: 84858338127     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2012.01.006     Document Type: Article

References (48)

1. A.Y. Manzur, T. Kuntzer, M. Pike, and A. Swan Glucocorticoid corticosteroids for Duchenne muscular dystrophy Cochrane Database Syst Rev 1 2008 CD003725
2. A.Y. Manzur, and F. Muntoni Diagnosis and new treatments in muscular dystrophies Postgrad Med J 85 2009 622 630
3. K. Bushby, R. Finkel, D.J. Birnkrant, L.E. Case, P.R. Clemens, and L. Cripe Diagnosis and management of Duchenne muscular dystrophy. Part 1. Diagnosis, and pharmacological and psychosocial management Lancet Neurol 9 2010 77 93
4. K. Bushby, R. Finkel, D.J. Birnkrant, L.E. Case, P.R. Clemens, and L. Cripe Diagnosis and management of Duchenne muscular dystrophy. Part 2. Implementation of multidisciplinary care Lancet Neurol 9 2010 177 189
5. C. Vandebrouck, N. Imbert, G. Duport, C. Cognard, and G. Raymond The effect of methylprednisolone on intracellular calcium of normal and dystrophic human skeletal muscle cells Neurosci Lett 269 1999 110 114 (Pubitemid 29335425)
6. F. Pasquini, C. Guerin, D. Blake, K. Davies, G. Karpati, and P. Holland The effect of glucocorticoids on the accumulation of utrophin by cultured normal and dystrophic human skeletal muscle satellite cells Neuromuscul Disord 5 1995 105 114
7. J.T. Kissel, M. McDermott, J.R. Mendell, W.M. King, S. Pandya, and R.C. Griggs Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy Neurology 57 2001 1434 1440 (Pubitemid 32995725)
8. R. Tawil, M. McDermott, S. Pandya, W. King, J. Kissel, and J.R. Mendell A pilot trial of prednisone in facioscapulohumeral muscular dystrophy. FSH-DY Group Neurology 48 1997 46 49 (Pubitemid 27039515)
9. M.C. Walter, H. Lochmuller, P. Reilich, T. Klopstock, R. Huber, and M. Hartard Creatine monohydrate in muscular dystrophies: a double-blind placebo controlled clinical study Neurology 54 2000 1848 1850 (Pubitemid 30428416)
10. M.D. Bonifati, G. Ruzza, P. Bonometto, A. Berardinelli, K. Gorni, and S. Orcesi A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy Muscle Nerve 23 2000 1344 1347
11. A.M. Connolly, A. Pestronk, S. Mehta, and M. Al-Lozi Primary alpha-sarcoglycan deficiency responsive to immunosuppression over three years Muscle Nerve 21 1998 1549 1553 (Pubitemid 28453150)
12. N. Darin, A.K. Kroksmark, A.C. Ahlander, A.R. Moslemi, A. Oldfors, and M. Tulinius Inflammation and response to steroid treatment in limb-girdle muscular dystrophy 2I Eur J Paediatr Neurol 11 2007 353 357 (Pubitemid 47534996)
13. K.R. Wagner, J.L. Fleckenstein, A.A. Amato, R.J. Barohn, K. Bushby, and D.M. Escolar A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy Ann Neurol 63 2008 561 571
14. S. Brunelli, C. Sciorati, G. D'Antona, A. Innocenzi, D. Covarello, and B.G. Galvez Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy Proc Natl Acad Sci USA 104 2007 264 269 (Pubitemid 46068020)
15. C. Sciorati, R. Buono, E. Azzoni, S. Casati, P. Ciuffreda, and G. D'Angelo Co-administration of ibuprofen and nitric oxide is an effective experimental therapy for muscular dystrophy, with immediate applicability to humans Br J Pharmacol 160 2010 1550 1560
16. C. Sciorati, D. Miglietta, R. Buono, V. Pisa, D. Cattaneo, and E. Azzoni A dual acting compound releasing nitric oxide (NO) and ibuprofen, NCX320, shows significant therapeutic effects in a mouse model of muscular dystrophy Pharmacol Res 64 2011 210 217
17. M. Wehling, M.J. Spencer, and J.G. Tidball A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice J Cell Biol 155 2001 123 131 (Pubitemid 34286213)
18. E.L. Finanger Hedderick, J.L. Simmers, A. Soleimani, E. Andres-Mateos, R. Marx, and D.C. Files Loss of sarcolemmal nNOS is common in acquired and inherited neuromuscular disorders Neurology 76 2011 960 967
19. J.D. Porter, S. Khanna, H.J. Kaminski, J.S. Rao, A.P. Merriam, and C.R. Richmonds A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice Hum Mol Genet 11 2002 263 272 (Pubitemid 34173355)
20. J.E. Anderson A role for nitric oxide in muscle repair: nitric oxide-mediated activation of muscle satellite cells Mol Biol Cell 11 2000 1859 1874 (Pubitemid 30307918)
21. C. Colussi, C. Mozzeta, A. Gurtner, B. Illi, J. Rosati, and S. Straino HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment Proc Natl Acad Sci USA 105 2008 19183 19187
22. R. Buono, C. Vantaggiato, V. Pisa, E. Azzoni, M.T. Bassi, and S. Brunelli Nitric oxide sustains long term skeletal muscle regeneration by regulating satellite cells fate via signalling pathways requiring Vangl2 and cyclic GMP Stem Cells 30 2012 197 209
23. A. Pisconti, S. Brunelli, M. Di Padova, C. De Palma, D. Deponti, and S. Baesso Follistatin induction by nitric oxide through cyclic GMP: a tightly regulated signaling pathway that controls myoblast fusion J Cell Biol 172 2006 233 244 (Pubitemid 43112970)
24. E. Nisoli, E. Clementi, C. Paolucci, V. Cozzi, C. Tonello, and C. Sciorati Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide Science 299 2003 896 899 (Pubitemid 36182449)
25. E. Nisoli, S. Falcone, C. Tonello, V. Cozzi, L. Palomba, and M. Fiorani Mitochondrial biogenesis by NO yields functionally active mitochondria in mammals Proc Natl Acad Sci USA 101 2004 16507 16512 (Pubitemid 39557743)
26. E. Nisoli, C. Tonello, A. Cardile, V. Cozzi, R. Bracale, and L. Tedesco Calories restriction promotes mitochondrial biogenesis by inducing the expression of eNOS Science 310 2005 314 317 (Pubitemid 41457197)
27. M. Wehling-Henricks, M. Oltmann, C. Rinaldi, K.H. Myung, and J.G. Tidball Loss of positive allosteric interactions between neuronal nitric oxide synthase and phosphofructokinase contributes to defects in glycolysis and increased fatigability in muscular dystrophy Hum Mol Genet 18 2009 3439 3451
28. C. Sciorati, B.G. Galvez, S. Brunelli, E. Tagliafico, S. Ferrari, and G. Cossu Ex vivo treatment with nitric oxide increases mesoangioblast therapeutic efficacy in muscular dystrophy J Cell Sci 119 2006 5114 5123 (Pubitemid 46085190)
29. C. Colussi, A. Gurtner, J. Rosati, B. Illi, G. Ragone, and G. Piaggio Nitric oxide deficiency determines global chromatin changes in Duchenne muscular dystrophy FASEB J 23 2009 2131 2141
30. A. Neubert, K. Verhamme, M.L. Murray, G. Picelli, Y. Hsia, and F.E. Sen The prescribing of analgesics and non-steroidal anti-inflammatory drugs in paediatric primary care in the UK, Italy and the Netherlands Pharmacol Res 62 2010 243 248
31. R. Dills, L.A. Anderson, and C.A. Pierce The role of nonsteroidal anti-inflammatory drugs in pediatric patients Pharmacol Res 65 2012 5 8
32. J.A. Franciosa Fixed combination isosorbide dinitrate-hydralazine for nitric-oxide-enhancing therapy in heart failure Expert Opin Pharmacother 7 2006 2521 2531 (Pubitemid 44939326)
33. K.C. Ferdinand Isosorbide dinitrate and hydralazine hydrochloride: a review of efficacy and safety Expert Rev Cardiovasc Ther 3 2005 993 1001 (Pubitemid 41754210)
34. K. Bushby Diagnosis and management of the limb girdle muscular dystrophies Pract Neurol 9 2009 314 323
35. M. Guglieri, V. Straub, K. Bushby, and H. Lochmüller Limb-girdle muscular dystrophies Curr Opin Neurol 21 2008 576 584
36. J. John Grading of muscle power: comparison of MRC and analogue scales by physiotherapists Int J Rehabil Res 7 1984 173 181 (Pubitemid 14046062)
37. C. Vuillerot, F. Girardot, C. Payan, J. Fermanian, J. Iwaz, and C. De Lattre Monitoring changes and predicting loss of ambulation in Duchenne muscular dystrophy with the Motor Function Measure Dev Med Child Neurol 52 2010 60 65
38. C. Bérard, C. Payan, I. Hodgkinson, and J. Fermanian A motor function measure for neuromuscular diseases. Construction and validation study Neuromuscul Disord 15 2005 463 470 (Pubitemid 40884470)
39. J.E. Ware SF-36 health survey update Spine 25 2000 3130 3139 (Pubitemid 32042945)
40. J.E. Ware, and C.D. Sherbourne The MOS 36-Item Short-Form Health Survey (SF-36) Med Care 30 1992 473 483
41. J.E. Ware, M. Kosinski, and S.K. Keller SF-36 Physical and Mental Health Summary Scales: a user's manual 1994 The Health Institute Boston
42. D. Henry, L.L. Lim, L.A. Garcia Rodriguez, S. Perez Gutthann, J.L. Carson, and M. Griffin Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis BMJ 312 1996 1563 1566 (Pubitemid 26188573)
43. C. Sciorati, G. Nistic, J. Meldolesi, and E. Clementi Nitric oxide effects on cell growth: GMP-dependent stimulation of the AP-1 transcription complex and cGMP-independent slowing of cell cycling Br J Pharmacol 122 1997 687 697 (Pubitemid 27453094)
44. M. Khairallah, R.J. Khairallah, M.E. Young, B.G. Allen, M.A. Gillis, and G. Danialou Sildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiency Proc Natl Acad Sci USA 105 2008 7028 7033 (Pubitemid 351754524)
45. N.P. Evans, S.A. Misyak, J.L. Robertson, J. Bassaganya-Riera, and R.W. Grange Immune-mediated mechanisms potentially regulate the disease time-course of Duchenne muscular dystrophy and provide targets for therapeutic intervention PM R 1 2009 755 768
46. J.C. van Deutekom, A.A. Janson, I.B. Ginjaar, W.S. Frankhuizen, A. Aartsma-Rus, and M. Bremmer-Bout Local dystrophin restoration with antisense oligonucleotide PRO051 N Engl J Med 357 2007 2677 2686
47. M. Kinali, V. Arechavala-Gomeza, L. Feng, S. Cirak, D. Hunt, and C. Adkin Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study Lancet Neurol 8 2009 918 928
48. V. Malik, L.R. Rodino-Klapac, L. Viollet, and J.R. Mendell Aminoglycoside-induced mutation suppression (stop codon readthrough) as a therapeutic strategy for Duchenne muscular dystrophy Ther Adv Neurol Disord 3 2010 379 389